Co-Authors
This is a "connection" page, showing publications co-authored by Lu Lu and Tianlei Ying.
Connection Strength
1.366
-
The impact of receptor-binding domain natural mutations on antibody recognition of SARS-CoV-2. Signal Transduct Target Ther. 2021 03 23; 6(1):132.
Score: 0.234
-
Fusion mechanism of 2019-nCoV and fusion inhibitors targeting HR1 domain in spike protein. Cell Mol Immunol. 2020 07; 17(7):765-767.
Score: 0.217
-
Neutralization of Zika virus by germline-like human monoclonal antibodies targeting cryptic epitopes on envelope domain III. Emerg Microbes Infect. 2017 Oct 11; 6(10):e89.
Score: 0.184
-
A Potent Germline-like Human Monoclonal Antibody Targets a pH-Sensitive Epitope on H7N9 Influenza Hemagglutinin. Cell Host Microbe. 2017 Oct 11; 22(4):471-483.e5.
Score: 0.184
-
Urgent development of effective therapeutic and prophylactic agents to control the emerging threat of Middle East respiratory syndrome (MERS). Emerg Microbes Infect. 2015 Jun 17; 4:e37.
Score: 0.157
-
Development of human neutralizing monoclonal antibodies for prevention and therapy of MERS-CoV infections. Microbes Infect. 2015 Feb; 17(2):142-8.
Score: 0.151
-
Exceptionally potent neutralization of Middle East respiratory syndrome coronavirus by human monoclonal antibodies. J Virol. 2014 Jul; 88(14):7796-805.
Score: 0.145
-
RBD-Fc-based COVID-19 vaccine candidate induces highly potent SARS-CoV-2 neutralizing antibody response. Signal Transduct Target Ther. 2020 11 27; 5(1):282.
Score: 0.057
-
Middle East respiratory syndrome coronavirus (MERS-CoV) entry inhibitors targeting spike protein. Virus Res. 2014 Dec 19; 194:200-10.
Score: 0.037